Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GC3111 Tdap Vaccine
NCT02813486Phase 2Unknown
- Sponsor
- GC Biopharma
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GC3111 in Tetanus, diphtheria, pertussis, sponsored by GC Biopharma. Status: unknown.
02
Drugs
GC3111
03
Conditions
Tetanusdiphtheriapertussis
Beyond the preview
Go deeper on NCT02813486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813486.